{"id":"toviaz-fesoterodine","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"15-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Urinary retention"},{"rate":"2-5","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fesoterodine blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing involuntary contractions. This anticholinergic action increases bladder capacity and reduces the urge to urinate, thereby decreasing episodes of urgency incontinence and frequency. The drug is a prodrug that is rapidly hydrolyzed to its active metabolite.","oneSentence":"Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:57.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT06110975","phase":"NA","title":"Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne Estrup Olesen","startDate":"2023-12-01","conditions":"Overactive Bladder, Deprescribing, PIMS","enrollment":72},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":"Overactive Bladder (OAB)","enrollment":5589},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT03946124","phase":"PHASE4","title":"Fall Prevention in Older Adults With OAB","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-07-25","conditions":"Overactive Bladder","enrollment":74},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT01936870","phase":"","title":"Drug Use Investigation for Toviaz","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-01","conditions":"Overactive Bladder (OAB)","enrollment":2521},{"nctId":"NCT04478357","phase":"PHASE1","title":"BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-11-12","conditions":"Neurogenic Detrusor Overactivity","enrollment":18},{"nctId":"NCT04452838","phase":"PHASE1","title":"Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-26","conditions":"Neurogenic Detrusor Overactivity","enrollment":37},{"nctId":"NCT01557244","phase":"PHASE3","title":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-02","conditions":"Urinary Bladder, Neurogenic","enrollment":181},{"nctId":"NCT02501928","phase":"PHASE3","title":"Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-05","conditions":"Urinary Bladder, Neurogenic","enrollment":12},{"nctId":"NCT01661166","phase":"PHASE4","title":"A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2012-01","conditions":"Prostate Adenocarcinoma","enrollment":3},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":"Overactive Bladder (OAB)","enrollment":805},{"nctId":"NCT01786967","phase":"PHASE3","title":"Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-09","conditions":"Urge Urinary Incontinence","enrollment":61},{"nctId":"NCT02240459","phase":"PHASE2","title":"A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-08","conditions":"Overactive Bladder, Mild Cognitive Impairment","enrollment":47},{"nctId":"NCT01499069","phase":"NA","title":"Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-02","conditions":"Overactive Bladder","enrollment":191},{"nctId":"NCT02385500","phase":"PHASE4","title":"Fesoterodine on Urgency Episodes in Parkinson's Disease Population","status":"TERMINATED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-09","conditions":"Urinary Bladder, Overactive, Parkinson Disease","enrollment":5},{"nctId":"NCT02676154","phase":"PHASE2","title":"Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2016-02-25","conditions":"Autonomic Dysreflexia","enrollment":15},{"nctId":"NCT02614482","phase":"PHASE3","title":"Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.","status":"COMPLETED","sponsor":"Stéphane Bolduc","startDate":"2015-10","conditions":"Overactive Bladder","enrollment":26},{"nctId":"NCT02327936","phase":"PHASE3","title":"Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children","status":"COMPLETED","sponsor":"Stéphane Bolduc","startDate":"2014-12","conditions":"Overactive Bladder","enrollment":62},{"nctId":"NCT00425100","phase":"PHASE3","title":"A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01","conditions":"Overactive Bladder","enrollment":516},{"nctId":"NCT01302054","phase":"PHASE4","title":"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Urinary Bladder, Overactive","enrollment":990},{"nctId":"NCT00911937","phase":"PHASE4","title":"A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-08","conditions":"Overactive Bladder","enrollment":963},{"nctId":"NCT00943735","phase":"","title":"This Is An Open-Label Study To Evaluate Fesoterodine Plus \"Your Way\" Patient Support Plan In Patients With Symptoms Of Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Overactive Bladder","enrollment":774},{"nctId":"NCT00691093","phase":"","title":"Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":823},{"nctId":"NCT00902187","phase":"PHASE1","title":"A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Treatment of Overactive Bladder","enrollment":36},{"nctId":"NCT00902681","phase":"PHASE1","title":"A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Treatment of Overactive Bladder","enrollment":36},{"nctId":"NCT00713921","phase":"EARLY_PHASE1","title":"Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients","status":"WITHDRAWN","sponsor":"Saint Thomas Health","startDate":"2009-09-15","conditions":"Urinary Incontinence, Bladder Dysfunction","enrollment":""},{"nctId":"NCT03662893","phase":"NA","title":"Behavioural Therapy With Checklist for Overactive Bladder","status":"COMPLETED","sponsor":"Ankara Training and Research Hospital","startDate":"2015-01-01","conditions":"Overactive Bladder","enrollment":120},{"nctId":"NCT00605319","phase":"PHASE4","title":"An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2010-01","conditions":"Bladder Outlet Obstruction","enrollment":17},{"nctId":"NCT00547378","phase":"PHASE4","title":"InSite for Over Active Bladder","status":"COMPLETED","sponsor":"MedtronicNeuro","startDate":"2007-10","conditions":"Urinary Incontinence, Urgency-frequency, Overactive Bladder","enrollment":571},{"nctId":"NCT01613170","phase":"PHASE4","title":"Premarin Versus Toviaz for Treatment of Overactive Bladder","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2012-04","conditions":"Overactive Bladder","enrollment":90},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT02262936","phase":"PHASE2, PHASE3","title":"Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older","status":"TERMINATED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2015-07","conditions":"Nocturia","enrollment":4},{"nctId":"NCT01566760","phase":"PHASE1","title":"A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05","conditions":"Urinary Bladder, Overactive","enrollment":24},{"nctId":"NCT00879398","phase":"","title":"Toviaz Post Marketing Surveillance Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Overactive Bladder","enrollment":3000},{"nctId":"NCT00444925","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-04","conditions":"Overactive Bladder","enrollment":1712},{"nctId":"NCT01367886","phase":"NA","title":"Comparative Urine Proteomic Studies of Overactive Bladder in Humans","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-08","conditions":"Overactive Bladder","enrollment":21},{"nctId":"NCT02160158","phase":"PHASE1","title":"Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT01925456","phase":"PHASE1","title":"Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05","conditions":"Overactive Bladder","enrollment":75},{"nctId":"NCT01260311","phase":"","title":"Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Over Active Bladder","enrollment":508},{"nctId":"NCT01302067","phase":"PHASE4","title":"A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Overactive Bladder","enrollment":2012},{"nctId":"NCT01605617","phase":"PHASE4","title":"Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2012-06","conditions":"Overactive Bladder","enrollment":4},{"nctId":"NCT01054222","phase":"PHASE4","title":"Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05","conditions":"Urinary Bladder, Overactive","enrollment":31},{"nctId":"NCT01091519","phase":"","title":"Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Urinary Bladder, Overactive","enrollment":781},{"nctId":"NCT00928070","phase":"PHASE4","title":"A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Overactive Bladder","enrollment":566},{"nctId":"NCT01161472","phase":"PHASE1","title":"A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Healthy","enrollment":20},{"nctId":"NCT01595152","phase":"NA","title":"Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2012-05","conditions":"Urinary Bladder, Overactive","enrollment":60},{"nctId":"NCT01578304","phase":"PHASE4","title":"Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2010-12","conditions":"Overactive Bladder","enrollment":207},{"nctId":"NCT01286454","phase":"PHASE1","title":"This Is A Study Of Bioavailability And Food Effect For Fesoterodine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency","enrollment":20},{"nctId":"NCT00798434","phase":"PHASE4","title":"A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Urinary Bladder, Overactive","enrollment":794},{"nctId":"NCT00857896","phase":"PHASE2","title":"Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Overactive Bladder, Neurogenic Detrusor Overactivity","enrollment":21},{"nctId":"NCT00862745","phase":"PHASE4","title":"Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-01","conditions":"Urge Urinary Incontinence, Overactive Bladder","enrollment":645},{"nctId":"NCT01042236","phase":"PHASE2","title":"Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Stress Urinary Incontinence","enrollment":22},{"nctId":"NCT00561951","phase":"PHASE2","title":"Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Overactive Bladder","enrollment":951},{"nctId":"NCT00911235","phase":"PHASE1","title":"The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence","enrollment":28},{"nctId":"NCT00914667","phase":"PHASE1","title":"The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Urinary Bladder, Overactive","enrollment":14},{"nctId":"NCT00546637","phase":"PHASE3","title":"Fesoterodine \"add-on\" Male Overactive Bladder Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Overactive Bladder Syndrome","enrollment":947},{"nctId":"NCT00611026","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":2417},{"nctId":"NCT00806494","phase":"PHASE4","title":"UK Study Assessing Flexible Dose Fesoterodine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Urinary Bladder, Overactive","enrollment":331},{"nctId":"NCT00832650","phase":"PHASE1","title":"Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Healthy","enrollment":60},{"nctId":"NCT00658684","phase":"PHASE3","title":"Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":153},{"nctId":"NCT00786240","phase":"PHASE1","title":"Phase1, Single Dose, Crossover Study to Determine Bioequivalence","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Healthy","enrollment":37},{"nctId":"NCT00807118","phase":"PHASE1","title":"Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-10","conditions":"Therapeutic Equivalency, Food","enrollment":108},{"nctId":"NCT00536484","phase":"PHASE3","title":"Fesoterodine Flexible Dose Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-08","conditions":"Overactive Bladder","enrollment":896},{"nctId":"NCT00220402","phase":"PHASE3","title":"Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00220376","phase":"PHASE3","title":"Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-04","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00220389","phase":"PHASE2","title":"Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-06","conditions":"Overactive Bladder","enrollment":""},{"nctId":"NCT00220363","phase":"PHASE3","title":"A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-01","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT00138723","phase":"PHASE3","title":"Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Overactive Bladder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"VISION BLURRED"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"PRURITUS"},{"count":2,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":2,"reaction":"APPLICATION SITE PAIN"},{"count":2,"reaction":"APPLICATION SITE PRURITUS"},{"count":2,"reaction":"APPLICATION SITE VESICLES"},{"count":2,"reaction":"ARTHRALGIA"}],"_approvalHistory":[],"publicationCount":337,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Toviaz"],"phase":"marketed","status":"active","brandName":"Toviaz (Fesoterodine)","genericName":"Toviaz (Fesoterodine)","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}